Takeaways from @evaluatepharma Orphan Drug Report 2020:

- Orphan drug sales: $119B (2018) → $217B (2024)
- Top companies: $BMY $JNJ $RHHBY $NVS $ABBV $TAK $PFE $SNY $VRTX $ALXN
- Top R&amp;D assets: Ide-cel, Risdiplam, Valrox, Efgart &amp; Liso-cel

Video link: https://t.co/XTjhhe3mJg https://t.co/rCpm3oRAgr